Invest in the future of the NHS EIS Advance Assurance from HMRC Earn 43%
On 1 November 2018 the law changed to allow doctors on the
General Medical Council's Specialist Register to prescribe unlicensed cannabis-based products for medicinal use (CBPM), where it is clinically appropriate and in the best interest of patients. Medicaleaf's™ vision is to be Europe's leading provider of health and
wellness cannabidiol innovations. We are seeking investment to fund
product manufacturing and distribution. LEARN MORE | |
Why Invest  | Already working with NHS and NIHR with a patent pending prescription technology. | | We will have a UK Network of 'Best Practice' medical centres where specialists can prescribe or oversee prescriptions of Medicinal Cannabis. | | Medicaleaf™ intends to generate revenue in excess of £5.34 million in this first trading year. | | Annual predicted net profit over sales metric of 'plus 43%'. | | Medicaleaf™ will have a 'post-raise' valuation of £20 million with expectations to reach a pre-floatation valuation of £200 million in three years' time. | | Offset over 50% of your investment with CGT and EIS relief. | | |
Medicinal Cannabis is available on the NHS if: | Your child has one of the rare forms of epilepsy that might be helped by medical cannabis | | You have spasticity from MS and treatments for this aren't helping | | You have vomiting or feel sick from chemotherapy | | |
Disclaimer: The information provided on this email is for information purposes only. The email and its content are not, and should not be deemed to be an invitation to engage in any financial activity. The email should not be construed as advice, or a personal recommendation. We are not authorised and regulated by the Financial Conduct Authority (FCA). The content of this email is not authorised under the Financial Services and Markets Act 2000 (FSMA). Reliance on this email for the purpose of engaging in any financial activity may expose an individual to a significant risk of losing all of the funds. UK residents wishing to participate in must fall into the category of sophisticated investor or high net worth individual as outlined by the Financial Conduct Authority (FCA). | |
No comments:
Post a Comment